NanoVibronix (UroShield)

Starting point

With UroShield, NanoVibronix had developed an ultrasound-based technology to reduce catheter-associated urinary tract infections — a clinically relevant topic in urology and intensive care, with a clear DRG revenue logic behind it (fewer nosocomial infections, lower complication rates and the corresponding revenue implications under Germany’s diagnosis-related group system).

Two things were missing for the German market: documented clinical evidence from German university hospitals, and a German digital presence in which hospital decision-makers could research the technology in the first place.

Mandate

MEX was engaged in 2024 with an integrated mandate: clinical studies at five KOL hospitals plus the parallel build-out of the German marketing and visibility base. The two tracks were not to run separately but to build on each other, so that study data could move directly into the German professional community.

Delivery — the clinical track

• KOL acquisition at five German university hospitals in urology and intensive care.
• Study design for the German sites, in coordination with local study leads and ethics committees.
• Multi-center coordination across all five sites (patient recruitment, data management, outcome reporting).
• MDR conformity of the study logistics, in preparation for the later listing phase.

Delivery — the visibility track (pre-Module 7)

Alongside the study, MEX built a German visibility base — conceptually already close to what was formalized in 2026 as Module 7, Digital Authority. Specifically:

• A German web presence under the NanoVibronix brand, in a clinical and technical register, with a sound technical SEO base.
• A keyword architecture for hospital decision-makers covering catheter-associated infections, antibiotic resistance and nosocomial hygiene.
• LinkedIn DACH outreach to heads of urology, intensive care physicians and hospital hygienists.
• Thought leadership content with clearly attributable statements, FAQ structures and cited sources — an early form of today’s AEO and GEO optimization.

Result and significance

The parallel architecture produced something that rarely works in conventional mandates: study data and visibility reinforced each other. Early research behavior by hospital decision-makers supplied data points for study communication; interim results from the five sites fed into LinkedIn posts by the local KOLs; SEO visibility on core indication keywords emerged before the study was published.

Out of this mandate, MEX formalized its seventh module, Digital Authority, in 2026 — with Julian Raab as co-managing director and RAAB Online-Marketing UG as the operational sister company.

Where this transfers

The NanoVibronix pattern is relevant for foreign MedTech manufacturers whose product is explanation-intensive, requires clinical evidence and at the same time has to be made visible in the German professional community. Conventionally the two are separated — the study mandate goes to a CRO, the marketing to an agency. In the MEX model both tracks converge in one integrated architecture (Modules 2, 3, 6 and 7).

We are happy to discuss it in a 30-minute discovery call.